(Total Views: 322)
Posted On: 10/09/2017 7:55:11 PM
Post# of 72446
Article - Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Targets $1 Billion Market
"Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) is developing Brilacidin to address a significant challenge that oral Mucositis presents to patients and their doctors every year. The condition is characterized by inflammation and ulceration, making it impossible for patients to speak or eat. Infected patients are also more susceptible to bacterial infections.
The frequent, painful and debilitating medical condition is commonly manifested in the treatment of head and neck cancer. Costs associated with the treatment of the condition places a substantial medical burden on the healthcare system because of lack of safe and efficacious therapies.
Oral Mucosity presents Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) with a $1 billion market opportunity as there are no approved medications for prevention of the disease."
http://www.theotcreporter.com/2017/10/09/inno...cmktsipix/
"Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) is developing Brilacidin to address a significant challenge that oral Mucositis presents to patients and their doctors every year. The condition is characterized by inflammation and ulceration, making it impossible for patients to speak or eat. Infected patients are also more susceptible to bacterial infections.
The frequent, painful and debilitating medical condition is commonly manifested in the treatment of head and neck cancer. Costs associated with the treatment of the condition places a substantial medical burden on the healthcare system because of lack of safe and efficacious therapies.
Oral Mucosity presents Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) with a $1 billion market opportunity as there are no approved medications for prevention of the disease."
http://www.theotcreporter.com/2017/10/09/inno...cmktsipix/
(1)
(0)
